Piolt study of usefulness of analysis of genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in safety of paclitaxel for the patients with alcohol intolerance - Role of genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in the alcohol-related toxicity of paclitaxel

Osaka International Cancer Institute0 sites20 target enrollmentApril 1, 2012

Overview

Phase: 未知
Intervention: Not specified
Conditions: Breast cancer, gastric cancer, ovarian cancer, non-small cell lung cancer, head and neck cancer, esophageal cancer
Sponsor: Osaka International Cancer Institute
Enrollment: 20
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

April 1, 2012

End Date

January 14, 2016

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\)Pregnancy, the possibility of pregnancy or breast feeding. 2\)Patients unable to take paclitaxcel because of significant cardiovascular abnormalities, renal dysfunction, hepatic insufficiency, uncontrolled hypertension, uncontrolled diabetes, bleeding tendency, active interstitial pneumonia ,etc. 3\)Febrile patients who are suspected to be infected. 4\)Prior treatment with paclitaxcel 5\)Patients unable to comply with the protocol, in the opinion of the investigator. 6\)Other contraindication to paclitaxcel. (1\)severe myelosuppression (2\)Known hypersensitivity to paclitaxcel or drugs which contain polyoxyethylene caster oil (e.g. ciclosporin injection). (3\) Patient taking disulfiram, cyanamide, carmofur, and procarbazine hydrochloride.